VolitionRx posts corporate deck outlining licensing-led strategy for Nu.Q diagnostics in cancer, sepsis, veterinary testing
VNRX•Sepsis program update
The sepsis program update said DETECSEPS is on track for first patient in Q3 2026, with reimbursement submission in preparation.
Pipeline priorities and 2026 targets
Pipeline priorities included human licensing discussions with more than a dozen diagnostics and liquid biopsy groups, targeting multiple deals in 2026.
Potential milestone tied to feline paper
The company highlighted a potential $5 million contractual milestone tied to a submitted feline paper, contingent on publication.
Investor deck highlights licensing-led strategy
VolitionRx's investor deck outlined an asset-light strategy focused on licensing Nu.Q diagnostics IP in cancer and sepsis.
- Commercial update flagged $23 million in licensing to date.
- Revenue was $1.4 million for H1 2026.
Related News
NYLI CBRE Global Infrastructure Megatrends Term Fund sets monthly distribution at $0.125 per share for August 2026
MEGI•
Interactive Strength Q2 FY26 adjusted EBITDA loss narrows to $0.6 million; revenue rises 445% to $6.6 million year over year
TRNR•
